Manufacturing regs for INDs
Executive Summary
FDA will issue a guidance and a direct final rule on good manufacturing practices for investigational new drug applications once the White House Office of Management & Budget has completed its review of the rule. The amount of information needed in the GMP filing "depends on the stage" of drug development, FDA said, noting that not all manufacturing work would have to be complete when a product enters Phase I and that early-stage submissions should focus on product identity as it relates to safety. The accompanying guidance will explain "the stepwise approach to meeting current [GMP] regulations"...
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.